Dr Reddys Laboratories Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-efb7d7d45f5a5e5db14d7de4.pdf

Key Takeaways


Semaglutide: The Relaunch

Israeli: "So I'm very confident. The confidence is based on orders that we already have. And we just obviously need to supply. The main issue was with our ability to scale up the API this problem is solved, and we shipped all the necessary API to our partner to do."

Abatacept: The Next Big Bet

Israeli: "I believe that a fair market share can be any number of 15% to 25% depends, of course, on the success of the launch."
Israeli: "You know, I'm 33 years in this business. And I had my share scars from these predictions. We feel good about the product. We feel good about the inspection. We feel good about the correspondence with the U.S. FDA. We want and be preparing to launch in December. If you ask me, is there a chance that we'll get a CRL, there is a chance."

Geographic Performance

MarketTrendCommentary
North America▼ 29% YoYLenalidomide decline drove the headline drop; the underlying base business ex-lenalidomide delivered strong double-digit growth on new launches including Sugammadex.
India▲ 17% YoYGrowth was driven by recent launches, including acquired brands, along with price increases and higher volumes; four brands featured in IPM top 50 new launches.
Emerging Markets▲ 24% YoYBroad-based growth from new product launches across markets, acquisitions, favorable currency, and milestone income from Russia.
Europe▼ 6% YoYPrice erosion in generics and the ongoing impact of the NRT operating model change post-Haleon carve-out weighed on performance; ex-NRT, Germany was a drag.
PSAI▼ 19% YoYAPI merchant business declined as older products lost demand and peptide customers shifted to finished goods; B2B finished product growth is recognized in other segments.

Margins: The Path Back to 25%

Israeli: "For me, by the way, 20% or 21% is not impressive. We always said that we want 25%. We are recovering from lenalidomide, and that's what we are going to be."

Biosimilars & Complex Generics Pipeline

Israeli: "But I'm kind of careful to promise because I got burned in the past when dealing with the approval of complex generics. And some of you who have been with us for many, many years, and you remember that. But let's say, we have some exciting products ahead."

Partnerships, CDMO & Other Updates


Guidance & Commitments

CommitmentSpecificsTimeline
Semaglutide relaunchRelaunch both directly and to partners, subject to successful validationNovember 2026
Gross margin range50% to 55%; Q2 at 52.1% is in that zoneComing quarters
R&D spend7% to 8% of revenuesComing quarters
SG&A level~32% of revenue with small changesComing quarters
EBITDA margin20%-plus sustainable; aiming for 25%; 21%-plus if semaglutide launches successfullyOngoing / near term
NRT growthHigh single-digit to double-digitOngoing
India growthHigh double-digit, higher than market growthOngoing
Abatacept U.S. launchLaunch upon approval; full ramp-up ~6 months afterDecember 2026 goal date
Abatacept subcutaneous filingSubmission to FDAFebruary-March 2027
Abatacept IV market share15% to 25% of IV market initiallyAt launch
CDMO revenue2x to 3x of current $100 mn-plus run rateNext 3-4 years
Capex~₹1,600-1,700 crores (lower than earlier ₹1,800 crore guidance)Full year FY27
Semaglutide device run rate1.2-1.5 crore pens, tentative, contingent on current volume success12 months from April
Raw material cost pressureIncreases in KSMs, solvents, freight to continue; no additional growth barring further geopoliticsQ3 and Q4

Key Metrics

MetricQ2 FY27
Consolidated revenue₹8,671 cr ($905 mn), -1.5% YoY and +7.4% QoQ
Underlying base business growth (ex-lenalidomide)Double-digit YoY, across North America, emerging markets and India
EBITDA margin20.6%, -614 bps YoY and +806 bps QoQ
Gross profit margin52.1%, -254 bps YoY and +562 bps QoQ
Global Generics gross margin56.2%
PSAI gross margin11.8%
Profit after tax₹925 cr ($97 mn), margin 10.7% on revenues
Diluted EPS₹11.1
R&D spend₹524 cr, -16% YoY, 6% of revenues; expected to be 7-8% in coming quarters
SG&A spend₹2,808 cr, +6% YoY, 32% of revenue
Effective tax rate25.6% vs 22.2% in Q2 FY26
North America generics revenue$264 mn, -29% YoY and +12% QoQ, 29% of overall revenue
India business revenue₹1,851 cr, +17% YoY and +8% QoQ, 21% of overall revenue
India moving quarterly total growth21% vs IPM 14.7%
India IPM rank8 for the quarter, 9 for the year (IQVIA Sep 2026)
Emerging markets revenue₹2,059 cr, +24% YoY and +12% QoQ, 25% of overall revenue
European business revenue (incl. NRT)€127 mn, -6% YoY and -3% QoQ, 16% of overall revenue
PSAI revenue$88 mn, -19% YoY and -3% QoQ, 10% of overall revenue
CDMO trailing 12-month revenue>$100 mn, expected to reach 2x-3x in 3-4 years
Net cash surplus₹2,502 cr ($261 mn) as of Sep 30, 2026
Operating working capital₹14,650 cr ($1.53 bn), +₹297 cr over Jun 30, 2026
Cash capex (quarter)₹186 cr ($19 mn); full-year guidance ₹1,600-1,700 cr
Semaglutide device guidance0.6-0.7 cr devices this year; tentative run rate of 1.2-1.5 cr pens for 12 months from April
Raw material and freight cost impact~100 bps drag on EBITDA
Rituximab market share in EuropeLow single digit